Adlai Nortye Group
ANL
14.05
-0.41
-2.84%
Adlai Nortye Group
US · ANL
#3309 by market cap
Listed 2023
14.05
-0.41
-2.84%
Live - 5344 symbols - heartbeat 296s ago
· 2026-10-08 08:39
Pre-market
14.05
0.00%
After-hours
14.05
0.00%
- Market cap
- 904.79M
- P/E (TTM)i
- -21.29
- P/Bi
- 4.21
- EPSi
- -1.11
- Div yieldi
- 0.00%
- 52W posi
- 80%
Reader sentiment
Are you bullish or bearish on ANL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -9.99, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 5 years
Margins
- Operating margin
- -713.96%
- Net margin
- -710.56%
Key ratios & quality
- Altman Z-Scorei
- -9.99
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 45.73M | 0 | 0 | 0 | 5.00M |
| Gross profit | -- | -- | -- | -- | -- |
| Selling & admin expenses | 12.45M | 12.43M | 14.82M | 9.44M | 7.79M |
| Research & development | 42.11M | 54.49M | 58.15M | 44.92M | 32.83M |
| Operating profit | -8.65M | -67.27M | -72.55M | -52.93M | -35.70M |
| Pretax profit | -56.68M | -58.79M | -109.23M | -51.87M | -35.53M |
| Tax | 0 | 0 | 0 | 0 | 0 |
| Net profit | -56.68M | -58.79M | -109.23M | -51.87M | -35.53M |
| Basic EPS | -2 | -2 | -8 | -2 | -1 |
| Diluted EPS | -1.54 | -1.59 | -7.56 | -1.62 | -1.11 |
| Line item | 2023-06 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.08M | -- | -- | -- | -- | -- |
| Research & development | 13.94M | -- | -- | -- | -- | -- |
| Operating profit | -16.86M | -- | -- | -- | -- | -- |
| Pretax profit | -63.40M | -- | -- | -- | -- | -- |
| Tax | 0 | -- | -- | -- | -- | -- |
| Net profit | -63.40M | -- | -- | -- | -- | -- |
| Basic EPS | -2 | -- | -- | -- | -- | -- |
| Diluted EPS | -1.72 | -- | -- | -- | -- | -- |
Balance sheet
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total current assets | 124.54M | 66.30M | 101.20M | 64.06M | 26.89M |
| Cash & ST investments | 117.94M | 64.05M | 98.50M | 60.91M | 8.06M |
| Inventory | -- | -- | -- | -- | -- |
| Total assets | 131.69M | 72.59M | 130.19M | 71.27M | 34.43M |
| Total current liabilities | 17.50M | 312.65M | 49.67M | 45.36M | 41.63M |
| Short-term debt | 11.29M | 5.31M | 31.08M | 26.80M | 25.25M |
| Long-term debt | -- | -- | -- | -- | -- |
| Total liabilities | 317,113,000.00 | 313,887,000.00 | 55,143,000.00 | 45,785,000.00 | 42,755,000.00 |
| Total equity | -185.43M | -241.29M | 75.05M | 25.49M | -8.32M |
| Retained earnings | -209.43M | -268.22M | -377.45M | -429.32M | -464.85M |
| Line item | 2023-06 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 61.53M | 100.28M | 64.06M | 65.48M | 26.89M | 240.88M |
| Cash & ST investments | 60.04M | 97.99M | 60.91M | 44.15M | 8.06M | 232.82M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 66.50M | 107.68M | 71.27M | 72.05M | 34.43M | 248.36M |
| Total current liabilities | 383.37M | 54.31M | 45.36M | 63.87M | 41.63M | 25.22M |
| Short-term debt | 20.50M | 39.53M | 26.80M | 44.31M | 25.25M | 18.39M |
| Long-term debt | -- | -- | -- | -- | -- | 7.34M |
| Total liabilities | 384,031,000.00 | 54,314,000.00 | 45,785,000.00 | 64,124,000.00 | 42,755,000.00 | 33,534,000.00 |
| Total equity | -317.54M | 53.37M | 25.49M | 7.92M | -8.32M | 214.83M |
| Retained earnings | -346.64M | -400.70M | -429.32M | -447.65M | -464.85M | -470.18M |
Cash flow
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | -3.03M | -43.22M | -56.65M | -51.82M | -33.45M |
| Depreciation & amortization | 1.83M | 2.04M | 2.22M | 1.87M | 1.41M |
| Free cash flow | -4.15M | -44.49M | -56.85M | -51.99M | -33.64M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | 97.37M | 0 | 91.78M | 0 | 0 |
| Ending cash balance | 64.13M | 42.76M | 91.49M | 60.90M | 8.06M |
| Line item | 2023-06 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -8.32M | -- | -- | -- | -- | -- |
| Depreciation & amortization | 653.00K | -- | -- | -- | -- | -- |
| Free cash flow | -8.38M | -- | -- | -- | -- | -- |
| Dividends paid | 0 | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 60.03M | -- | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -98.90 | -414.01 |
| ROA %i | -43.04 | -57.56 | -103.43 | -51.49 | -67.22 |
| ROIC %i | -- | -- | -- | -61.01 | -96.21 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- |
| EBIT margin %i | -121.03 | -- | -2,068.74 | -- | -680.80 |
| FCF / sales %i | -- | -- | -- | -- | -- |
| Current ratioi | 7.12 | 0.21 | 2.04 | 1.41 | 0.65 |
| Quick ratioi | 6.85 | 0.21 | 1.99 | 1.37 | 0.23 |
| Debt / assetsi | 10.13 | 9.01 | 24.23 | 38.20 | 76.60 |
| LT debt / equityi | -- | -- | 0.63 | 1.67 | -- |
| Interest coveragei | -41.39 | -134.77 | -130.77 | -25.68 | -22.88 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- |
| Line item | 2023-06 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -98.90 | -138.99 | -414.01 | -20.23 |
| ROA %i | -184.44 | -62.08 | -51.49 | -47.40 | -67.22 | -14.06 |
| ROIC %i | -- | -- | -61.01 | -56.23 | -96.21 | -14.50 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -1,038.56 | -- | -- | -680.80 | -118.03 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.16 | 1.85 | 1.41 | 1.03 | 0.65 | 9.55 |
| Quick ratioi | 0.16 | 1.85 | 1.37 | 0.74 | 0.23 | 9.55 |
| Debt / assetsi | 31.82 | 36.71 | 38.20 | 61.86 | 76.60 | 10.75 |
| LT debt / equityi | -- | -- | 1.67 | 3.24 | -- | 3.87 |
| Interest coveragei | -295.25 | -34.76 | -25.68 | -23.85 | -22.88 | -17.51 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Business of developing innovative targeted and immune- modulating cancer therapies100.00%
Region
United States100.00%
Quote time 2026-10-08 08:39:08 · For reference only, not investment advice and not tailored to your situation.